Global Oncology Academy

The Global Oncology Academy (GOA) is an educational platform for physicians and other healthcare professionals involved in oncology. Its mission is to increase knowledge regarding the disease course of specific cancers and address key elements for successful management. The GOA series will also share the science around innovations in combination therapies, oncology strategies, and new developments.

For more information about GOA, visit www.globaloncologyacademy.org.

Episodes 1-16 of 150

Exercise in Multiple Myeloma: Balancing Benefits and Safety
Exercise in Multiple Myeloma: Balancing Benefits and Safety
Project Oncology®
Exercise in Multiple Myeloma: Balancing Benefits and Safety
- Jens Hillengass, MD, PhD
Advances in Prostate Cancer Care: Genetic Testing, Teamwork, and ARPIs
Advances in Prostate Cancer Care: Genetic Testing, Teamwork, and ARPIs
Global Oncology Academy
Advances in Prostate Cancer Care: Genetic Testing, Teamwork, and ARPIs
- Neal Shore, MD
mCRPC Care: Predicting Outcomes with a Novel Cell-Free DNA Sequencing Assay
mCRPC Care: Predicting Outcomes with a Novel Cell-Free DNA Sequencing Assay
Global Oncology Academy
mCRPC Care: Predicting Outcomes with a Novel Cell-Free DNA Sequencing Assay
- Scott Dehm, PhD
MinuteCE®
Metastatic Pancreatic Ductal Adenocarcinoma (PDAC): From Diagnosis to Treatment
0.25 credits 2 episodes
- Efrat Dotan, MD
- Shubham Pant, MD, MBBS
0.25 credits 2 episodes
Chemotherapy Strategies for Metastatic PDAC
Chemotherapy Strategies for Metastatic PDAC
MinuteCE®
Chemotherapy Strategies for Metastatic PDAC
0.25 program credits
- Efrat Dotan, MD
- Shubham Pant, MD, MBBS
0.25 program credits
Diagnosis and Management of Metastatic PDAC
Diagnosis and Management of Metastatic PDAC
MinuteCE®
Diagnosis and Management of Metastatic PDAC
0.25 program credits
- Efrat Dotan, MD
- Shubham Pant, MD, MBBS
0.25 program credits
Predictive Models for CAR T-Cell Therapy: Personalizing R/R LBCL Care
Predictive Models for CAR T-Cell Therapy: Personalizing R/R LBCL Care
Project Oncology®
Predictive Models for CAR T-Cell Therapy: Personalizing R/R LBCL Care
- Charles Turck, PharmD, BCPS, BCCCP
- Matthew Matasar, MD
Sacituzumab Govitecan for mTNBC: A Review of Real-World Efficacy and Safety Data
Sacituzumab Govitecan for mTNBC: A Review of Real-World Efficacy and Safety Data
Project Oncology®
Sacituzumab Govitecan for mTNBC: A Review of Real-World Efficacy and Safety Data
- Charles Turck, PharmD, BCPS, BCCCP
- Paolo Tarantino, MD
Mastering CAR-T Cell Therapy in R/R Large B-Cell Lymphoma: Adverse Event Management
Mastering CAR-T Cell Therapy in R/R Large B-Cell Lymphoma: Adverse Event Management
Project Oncology®
Mastering CAR-T Cell Therapy in R/R Large B-Cell Lymphoma: Adverse Event Management
- Charles Turck, PharmD, BCPS, BCCCP
- Sairah Ahmed, MD
- Caron A. Jacobson, MD
Newly Diagnosed Multiple Myeloma: The Prognostic Significance of Lymphopenia
Newly Diagnosed Multiple Myeloma: The Prognostic Significance of Lymphopenia
Project Oncology®
Newly Diagnosed Multiple Myeloma: The Prognostic Significance of Lymphopenia
Preventing MGUS/SMM Progression to Multiple Myeloma with Dietary Interventions
Preventing MGUS/SMM Progression to Multiple Myeloma with Dietary Interventions
Global Oncology Academy
Preventing MGUS/SMM Progression to Multiple Myeloma with Dietary Interventions
Targeting HER2-Mutant NSCLC with Trastuzumab Deruxtecan: Initial Study Findings
Targeting HER2-Mutant NSCLC with Trastuzumab Deruxtecan: Initial Study Findings
Project Oncology®
Targeting HER2-Mutant NSCLC with Trastuzumab Deruxtecan: Initial Study Findings
- Jacob Sands, MD
- Julia Rotow, MD
Preventing Adverse Events in CAR T-Cell Therapy: The Evolution of Safety Protocols
Preventing Adverse Events in CAR T-Cell Therapy: The Evolution of Safety Protocols
Project Oncology®
Preventing Adverse Events in CAR T-Cell Therapy: The Evolution of Safety Protocols
- Tara Graff, DO, MS
- Charles Turck, PharmD, BCPS, BCCCP
Early-Stage Breast Cancer Care: Treatment Selection Strategies and Challenges
Early-Stage Breast Cancer Care: Treatment Selection Strategies and Challenges
Project Oncology®
Early-Stage Breast Cancer Care: Treatment Selection Strategies and Challenges
- Adrienne Waks, MD
Treating Second-Line NSCLC: The Efficacy of ADCs Targeting Predictive Biomarkers
Treating Second-Line NSCLC: The Efficacy of ADCs Targeting Predictive Biomarkers
Project Oncology®
Treating Second-Line NSCLC: The Efficacy of ADCs Targeting Predictive Biomarkers
- Charles Turck, PharmD, BCPS, BCCCP
- Laura Alder, MD
Treating NSCLC with Durvalumab, Chemotherapy, and Novel Agents: Preliminary Results
Treating NSCLC with Durvalumab, Chemotherapy, and Novel Agents: Preliminary Results
Project Oncology®
Treating NSCLC with Durvalumab, Chemotherapy, and Novel Agents: Preliminary Results
- Charles Turck, PharmD, BCPS, BCCCP
- Thomas Egenod, MD